Brief ReportAnti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Under an Elsevier user license
open archive
Keywords
Nivolumab
Immune checkpoint inhibitor
Immunotherapy
Tuberculosis
Opportunistic infection
Cited by (0)
Disclosure: The authors declare no conflict of interest.
© 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.